Lupin Pharma yesterday announced that the US Food and Drug Administration (USFDA) has approved the company’s supplemental New Drug Application (sNDA) to expand the use of Solosec (secnidazole) in the treatment of Bacterial Vaginosis (BV) for female patients 12 years of age and older and in the treatment of trichomoniasis for all patients 12 years of age and older, Lupin notified via a statement.

The statement also informed that BV is a common vaginal infection and trichomoniasis is the most common non-viral, curable sexually transmitted infection in the US.

The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription anti-microbial agent approved for the treatment of both trichomoniasis and BV.

“The FDA’s approval expands the indication for Solosec to treat adolescents and builds upon our commitment to support women’s health.

This expansion brings to healthcare professionals a treatment option for both BV and trichomoniasis in adolescents which provides a complete course of therapy in a single dose, one which helps to address gaps in care related to adherence, and may reduce risk factors associated with BV and trichomoniasis, such as other Sexually Transmitted Diseases (STIs),” said Tom Merriam, Executive Director – Specialty, Lupin, in the statement.

Must read

USFDA gives nod to this Molecule to treat retinal vascular diseases

USFDA authorised Bebtelovimab as antibody drug

USFDA gives nod to Zydus for Roflumilast Tablets

USFDA gives nod to Lupin for Arformoterol Tartrate inhalation solution

USFDA gives nod to Granules India for generic antidepressant drug

USFDA gives tentative nod to Alembic for Fesoterodine fumarate extended-release tablets

India reports outbreak of H5N1 Bird Flu Virus

USFDA gives nod to this Molecule to treat retinal vascular diseases

Govt recommends continuation of anti-dumping duty on import of Amoxycillin

Drug recall: Red Mammoth capsules recalled due to this reason

Molnupiravir effective against Omicron, could reduce deaths: Study

Pharmacists oppose draft amendment allowing class12th pass outs to sell Medical devices

0.31% of drug samples tested in 2020-21 declared as spurious or adulterated

USFDA authorised Bebtelovimab as antibody drug

Govt to make registration certificate mandatory for sale of medical devices

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/02/19/usfda-gives-nod-to-lupin-for-snda-for-solosec/